Evaluation of a Non-Invasive Device for Early Detection of Atopic Dermatitis Flares
ConditionAtopic Dermatitis
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age12-89
SponsorCastle Biosciences Incorporated
About this trial
This study will collect skin measurements from people with atopic dermatitis (AD) using the investigational Nevisense Go device. Participants aged 12 to 89 years with a history of AD flares will use the device at home for about 90 days. Participants will complete device measurements, electronic diary entries, and up to five in-person study visits. The study is based on the idea that changes in skin barrier function may occur before an AD flare becomes visible or symptoms begin. Information collected during the study, including device measurements, diary entries, and investigator assessments, will be used to evaluate whether these changes may help estimate the likelihood of an AD flare before visible signs or symptoms occur.
Eligibility criteria
Qualifiers
Are 12 to 89 years old.
Have been diagnosed with atopic dermatitis (eczema).
Have had at least one atopic dermatitis flare within the past 2 months.
Are willing and able to use the Nevisense Go device at home, complete an electronic symptom diary, and attend study visits.
Disqualifiers
Are unwilling or unable to avoid applying creams, lotions, ointments, or soap to measurement areas for 6 hours before measurements.
Do not have suitable skin areas for study measurements.
Have another skin condition that may affect study assessments.
Are pregnant.
Trial design
Treatments tested in this trial
- Nevisense electrical impedance spectroscopy
Treatment groups
No treatment groups listed
Sponsors and collaborators
Castle Biosciences Incorporated
Lead sponsor
SciBase AB
Collaborator
Source ClinicalTrials.gov